Johnson & Johnson: Sclerosis trials

The registry lists 12 Sclerosis studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 2 3Phase 3 6Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisCompletedNCT03232073Phase 3Results posted
• Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)TerminatedNCT02907177Phase 3Results posted
• Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisCompletedNCT02425644Phase 3Results posted
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsTerminatedNCT01474122Phase 3Results posted
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsCompletedNCT01474109Phase 3Results posted
• Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01093326Phase 2Results posted
• Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01006265Phase 2Results posted
• A Safety and Efficacy Study of CNTO1275 in Patients With Multiple SclerosisCompletedNCT00207727Phase 2Results posted
• Digital UlcerationCompletedNCT01377090
• Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)TerminatedNCT00706082
• Pulmonary Artery Remodelling With BosentanCompletedNCT00595049Phase 4
• Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With SclerodermaCompletedNCT00077584Phase 3